Patients with NYHA classification > II who require treatment with natriuretic peptide
Conditions
Interventions
Observation group within natriuretic peptide treatment:None
Sponsors
West China Hospital, Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18; 2. Participants with NYHA classification > II who require treatment with natriuretic peptide; 3. Informed consent of the patients or their families and approval by the ethics committee.
Exclusion criteria
Exclusion criteria: 1. Maternal; 2. Participants with an expected survival time of less than 72 hours; 3. Participants 80 years of age (older participants have greater variation in physiological functioning, which may bias study results); 4. Irreversible heart disease (e.g., end-stage cardiomyopathy) existed prior to the disease; 5. Participants in whom hemodynamic, tests and ultrasound indices cannot be taken prior to the application of natriuretic peptide.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Blood pressure;Heart rate;Urine output;Mean arterial pressure(MAP);Central venous pressure (CVP);Central venous oxygen saturation;Arteriovenous carbon dioxide partial pressure difference;24h access;Type, dosage and duration of vasoactive drug use, etc.;Type, dosage and duration of cardiac drug use, etc.;Myocardial markers;Left Ventricular Ejection Fraction(LVEF);Stroke Volume(SV);Cardiac Output Index (CI);Left Ventricular Outflow Tract Velocity-Time Integral(LVOT-VTI);Tricuspid Annular Plane Systolic Excursion(TAPSE);Mitral Annular Systolic Excursion(MAPSE);Mitral Inflow E/A Ratio (E/A);E/e' Ratio;Inferior vena cava (IVC) long-axis and short-axis measurements and collapsibility index;Valve regurgitation conditions;Cardiac contraction (presence of abnormal segmental contractions);Ultrasound presentation of the lungs;ICU 28-day mortality rate;Duration of mechanical ventilation;Costs during ICU stay;Total hospitalisation costs;Sexes;Age;Primary disease;Antecedent history;Acute Physiology And Chronic Health Evaluation II (APACHE II);Sequential Organ Failure Assessment (SOFA);Intracranial blood flow;Renal and gastrointestinal perfusion (microcirculation improvement);The time required for stable blood pressure;Significant correction time for shock;Duration of shock;Occurrence and number of organs affected by MODS;Total difference in infusion volume (fluid balance) within 7 days after admission to the ICU; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood test;Liver function;Renal function;Coagulation;Arterial blood gases (pH, oxygen partial pressure, carbon dioxide partial pressure, lactate, oxygenation index);Mechanical ventilation parameters;Surveillance of site of infection and infectious agents (sputum culture, blood culture, bronchoalveolar lavage culture, NGS, PCR, etc.);ICU 14-day mortality rate; | — |
Countries
China
Contacts
Public ContactYin Wanhong
West China Hospital of Sichuan University
Outcome results
None listed